{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T17:23:11Z","timestamp":1793467391636,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T00:00:00Z","timestamp":1588896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T00:00:00Z","timestamp":1588896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s00228-020-02872-6","type":"journal-article","created":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T20:02:30Z","timestamp":1588968150000},"page":"1053-1058","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Influence of CYP2C9 and CYP2A6 on plasma concentrations of valproic acid: a meta-analysis"],"prefix":"10.1007","volume":"76","author":[{"given":"Ha Young","family":"Yoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Hyoung","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nari","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Min","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Sun","family":"Gwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,8]]},"reference":[{"key":"2872_CR1","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2165\/00023210-200216100-00004","volume":"16","author":"E Perucca","year":"2002","unstructured":"Perucca E (2002) Pharmacological and therapeutic properties of valproate. CNS Drugs 16:695\u2013714","journal-title":"CNS Drugs"},{"key":"2872_CR2","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.pharep.2016.12.003","volume":"69","author":"W Jawien","year":"2017","unstructured":"Jawien W, Wilimowska J, Klys M, Piekoszewski W (2017) Population pharmacokinetic modelling of valproic acid and its selected metabolites in acute VPA poisoning. Pharmacol Rep 69:340\u2013349","journal-title":"Pharmacol Rep"},{"key":"2872_CR3","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/bcpt.12776","volume":"121","author":"M Zhao","year":"2017","unstructured":"Zhao M, Zhang T, Li G, Qiu F, Sun Y, Zhao L (2017) Associations of CYP2C9 and CYP2A6 polymorphisms with the concentrations of valproate and its hepatotoxin metabolites and valproate-induced hepatotoxicity. Basic Clin Pharmacol Toxicol 121:138\u2013143","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2872_CR4","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.eplepsyres.2017.02.015","volume":"132","author":"C Wang","year":"2017","unstructured":"Wang C, Wang P, Yang LP, Pan J, Yang X, Ma HY (2017) Association of CYP2C9, CYP2A6, ACSM2A, and CPT1A gene polymorphisms with adverse effects of valproic acid in Chinese patients with epilepsy. Epilepsy Res 132:64\u201369","journal-title":"Epilepsy Res"},{"key":"2872_CR5","first-page":"698","volume":"283","author":"AJ Sadeque","year":"1997","unstructured":"Sadeque AJ, Fisher MB, Korzekwa KR, Gonzalez FJ, Rettie AE (1997) Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid. J Pharmacol Exp Ther 283:698\u2013703","journal-title":"J Pharmacol Exp Ther"},{"key":"2872_CR6","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3109\/03602539308993982","volume":"25","author":"SA Wrighton","year":"1993","unstructured":"Wrighton SA, Vandenbranden M, Stevens JC, Shipley LA, Ring BJ, Cashman JR, Rettie AE (1993) In vitro methods for assessing human hepatic drug metabolism: their use in drug development. Drug Metab 25:453\u2013484","journal-title":"Drug Metab"},{"key":"2872_CR7","unstructured":"Baillie TA, Sheffels PR (1995) Valproic acid chemistry and biotransformation. In: Levy RH, Mattson RH, Meldrum BS (ed) Antiepileptic drugs, 4th edn. New York: Raven Press, pp 589\u2013604"},{"key":"2872_CR8","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.clinbiochem.2013.06.012","volume":"46","author":"RM Nanau","year":"2013","unstructured":"Nanau RM, Neuman MG (2013) Adverse drug reactions induced by valproic acid. Clin Biochem 46:1323\u20131338","journal-title":"Clin Biochem"},{"key":"2872_CR9","doi-asserted-by":"publisher","first-page":"452","DOI":"10.3109\/15376516.2010.497977","volume":"20","author":"N Amini-shirazi","year":"2010","unstructured":"Amini-shirazi N, Ghagremani MH, Ahmadkhaniha R, Mandegary A, Dadgar A, Abdollahi M, Shadnia S, Pakdaman H, Kebriaeezadeh A (2010) Influence of CYP2C9 polymorphism on metabolism of valproate and its hepatotoxin metabolite in Iranian patients. Toxicol Mech Methods 20:452\u2013457","journal-title":"Toxicol Mech Methods"},{"key":"2872_CR10","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 6:264\u2013269","journal-title":"Ann Intern Med"},{"key":"2872_CR11","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603\u2013605","journal-title":"Eur J Epidemiol"},{"key":"2872_CR12","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.clineuro.2010.01.002","volume":"112","author":"L Tan","year":"2010","unstructured":"Tan L, Yu JT, Sun YP, Ou JR, Song JH, Yu Y (2010) The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients. Clin Neurol Neurosurg 112:320\u2013323","journal-title":"Clin Neurol Neurosurg"},{"key":"2872_CR13","doi-asserted-by":"publisher","first-page":"536","DOI":"10.2133\/dmpk.DMPK-11-NT-144","volume":"27","author":"Y Guo","year":"2012","unstructured":"Guo Y, Hu C, He X, Qiu F, Zhao L (2012) Effests of UGT2B7, and CYP2C9 genotypes on plasma concentration of valproic acid in Chinese children with epilepsy. Drug Metab Pharmacokinet 27:536\u2013542","journal-title":"Drug Metab Pharmacokinet"},{"key":"2872_CR14","first-page":"82","volume":"46","author":"Q Liao","year":"2013","unstructured":"Liao Q, Shi J, Zhang Y, Xiaolei LI, Liu S, Qiu J (2013) Effects of cytochrome P450 isozymes 2A6, 2B6, 2C9 and 2C19 genetic polymorphisms on plasma concentration of sodium valproate. Chin J Neurol 46:82\u201386","journal-title":"Chin J Neurol"},{"key":"2872_CR15","first-page":"745","volume":"11","author":"Y Sun","year":"2005","unstructured":"Sun Y, Tan L, Song J (2005) Effect of CYP2A6 genetic polymorphisms on serum concentration of sodium valproate. Chin J Neurol 11:745\u2013747","journal-title":"Chin J Neurol"},{"key":"2872_CR16","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/sj.tpj.6500210","volume":"3","author":"PC Ho","year":"2003","unstructured":"Ho PC, Abbott FS, Zanger UM, Chang TK (2003) Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes. Pharmacogenomics J 3:335\u2013342","journal-title":"Pharmacogenomics J"},{"key":"2872_CR17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/1755-5922.12230","volume":"35","author":"J Zhang","year":"2017","unstructured":"Zhang J, Tian L, Huang J, Huang S, Chai T, Shen J (2017) Cytochrome P450 2C9 gene polymorphism and warfarin maintenance dosage in pediatric patients: a systematic review and meta-analysis. Cardiovasc Ther 35:26\u201332","journal-title":"Cardiovasc Ther"},{"key":"2872_CR18","first-page":"51","volume":"11","author":"CE Silvado","year":"2018","unstructured":"Silvado CE, Terra VC, Twardowschy CA (2018) CYP2C9 polymorphisms in epilepsy: influence on phenytoin treatment. Pharmgenomics Pers Med 11:51\u201358","journal-title":"Pharmgenomics Pers Med"},{"key":"2872_CR19","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1046\/j.1365-2125.2002.01667.x","volume":"54","author":"R Yoshida","year":"2002","unstructured":"Yoshida R, Nakajima M, Watanabe Y, Kwon JT, Yokoi T (2002) Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism. Br J Clin Pharmacol 54:511\u2013517","journal-title":"Br J Clin Pharmacol"},{"key":"2872_CR20","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/clpt.2011.174","volume":"90","author":"Z Desta","year":"2011","unstructured":"Desta Z, Kreutz Y, Nguyen AT, Li L, Skaar T, Kamdem LK, Henry NL, Hayes DF, Storniolo AM, Stearns V, Hoffmann E, Tyndale RF, Flockhart DA (2011) Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age. Clin Pharmacol Ther 90:693\u2013700","journal-title":"Clin Pharmacol Ther"},{"key":"2872_CR21","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1111\/epi.13011","volume":"56","author":"T Budi","year":"2015","unstructured":"Budi T, Toth K, Nagy A, Szever Z, Kiss A, Temesvari M, Hafra E, Garami M, Tapodi A, Monostory K (2015) Clinical significance of CYP2C9-status guided valproic acid therapy in children. Epilepsia 56:849\u2013855","journal-title":"Epilepsia"},{"key":"2872_CR22","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/toxsci\/66.2.185","volume":"66","author":"G Ginsberg","year":"2002","unstructured":"Ginsberg G, Hattis D, Sonawane B, Russ A, Banati P, Kozlak M, Smolenski S, Goble R (2002) Evaluation of child\/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol Sci 66:185\u2013200","journal-title":"Toxicol Sci"},{"key":"2872_CR23","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/00008571-199608000-00007","volume":"6","author":"TH Sullivan-Klose","year":"1996","unstructured":"Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, Goldstein JA (1996) The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6:341\u2013349","journal-title":"Pharmacogenetics"},{"key":"2872_CR24","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1097\/00008571-200409000-00006","volume":"14","author":"KA Schoedel","year":"2004","unstructured":"Schoedel KA, Hoffmann EB, Rao Y, Sellers EM, Tyndale RF (2004) Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics 14:615\u2013626","journal-title":"Pharmacogenetics"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-02872-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-020-02872-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-02872-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T23:25:57Z","timestamp":1620429957000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-020-02872-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,8]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["2872"],"URL":"https:\/\/doi.org\/10.1007\/s00228-020-02872-6","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,8]]},"assertion":[{"value":"22 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}